Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Documenti analoghi

• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  di: Mario Luca Morieri, et al.
  Pubblicazione: (2026)
• Targeting gut‐derived NETosis : A paradigm shift in understanding metformin's therapeutic action
  di: Ludovica Migliozzi, et al.
  Pubblicazione: (2026)
• Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts
  di: Gian Paolo Fadini, et al.
  Pubblicazione: (2024)
• SemaGBA : A System Dynamics Model of the Semaglutide‐Responsive Gut‐Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight
  di: Vivan C. W. Kennis, et al.
  Pubblicazione: (2026)
• Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes
  di: Zhenxi Wang, et al.
  Pubblicazione: (2026)